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Abstract
Response to antidepressant treatment in major depressive disorder (MDD) cannot be pre-
dicted currently, leading to uncertainty in medication selection, increasing costs, and pro-
longed suffering for many patients. Despite tremendous efforts in identifying response-
associated genes in large genome-wide association studies, the results have been fairly
modest, underlining the need to establish conceptually novel strategies. For the identifica-
tion of transcriptome signatures that can distinguish between treatment responders and
nonresponders, we herein submit a novel animal experimental approach focusing on
extreme phenotypes. We utilized the large variance in response to antidepressant treatment
occurring in DBA/2J mice, enabling sample stratification into subpopulations of good and
poor treatment responders to delineate response-associated signature transcript profiles in
peripheral blood samples. As a proof of concept, we translated our murine data to the tran-
scriptome data of a clinically relevant human cohort. A cluster of 259 differentially regulated
genes was identified when peripheral transcriptome profiles of good and poor treatment
responders were compared in the murine model. Differences in expression profiles from
baseline to week 12 of the human orthologues selected on the basis of the murine transcript
signature allowed prediction of response status with an accuracy of 76% in the patient
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population. Finally, we show that glucocorticoid receptor (GR)-regulated genes are signifi-
cantly enriched in this cluster of antidepressant-response genes. Our findings point to the
involvement of GR sensitivity as a potential key mechanism shaping response to antide-
pressant treatment and support the hypothesis that antidepressants could stimulate resil-
ience-promoting molecular mechanisms. Our data highlight the suitability of an appropriate
animal experimental approach for the discovery of treatment response-associated path-
ways across species.
Author summary
Major depression is the second leading cause of disability worldwide. However, only one-
third of patients with depression benefit from the first antidepressant compound they are
prescribed. It is a fundamental problem that the outcomes of individual antidepressant
treatments are still highly unpredictable. In clinical studies, discovery of biomarkers for
antidepressant response is hampered by confounding factors such as the heterogeneity of
the disease phenotype and additional environmental factors, e.g., previous life events and
different schedules of psychopharmacological treatment, which reduce the power to detect
true response biomarkers. To overcome some of these limitations, we have established a
conceptually novel approach that allows the selection of extreme phenotypes in an antide-
pressant-responsive mouse strain. In the first step, we identify signatures in the transcrip-
tome of peripheral blood associated with responses following stratification into good and
poor treatment responders. As proof of concept, we translate the murine data to a popula-
tion of depressed patients. We show that differences in expression profiles from baseline
to week 12 of the human orthologues predict response status in patients. We finally pro-
vide evidence that sensitivity of the glucocorticoid receptor could be a potential key mech-
anism shaping response to antidepressant treatment.
Introduction
A “one size fits all” approach is not effective or efficient in the treatment of major depressive
disorder (MDD). Although it would be ideal to tailor available treatments to individual
patients [1], patient-level antidepressant treatment outcomes are still highly unpredictable [2].
Identification of biomarkers predictive of individual treatment response or molecular bio-
signatures associated with response would dramatically improve the quality of care for MDD
[3]. These biomarkers could also be expected to significantly reduce both treatment and loss-
of-productivity costs. The latter become increasingly important because MDD has been shown
to be the second leading cause of disability worldwide [4]. Finally, biomarkers could allow
patient stratification and enable the selection of pathophysiologically distinct patient sub-
groups to allow optimized treatment choices based on biology. Such biomarkers could also
inform the development of new interventions specifically targeting disease mechanisms in
these subgroups.
Conceivably, useful biomarkers for treatment response in depression could be developed
through blood-based biomarkers, including genetic approaches, although psychophysiological
and neuroimaging approaches are also promising [5]. However, despite considerable efforts,
including large-scale hypothesis-free, genome-wide approaches during the past years [6, 7], no
biological or genetic predictors of sufficient clinical utility have been identified for routine
Biosignatures associated with antidepressant response
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clinical use. Thus, the most effective treatment for each patient is currently identified through
a trial and error process [2].
Among the potential barriers to the development of clinically useful biomarkers in depres-
sion, the following 3 have been identified as being most important. First, current symptom-
based diagnoses likely group pathophysiologically distinct patients [8], leading to considerable
heterogeneity among patients diagnosed with MDD [9, 10]. Second, there are a number of
confounding environmental factors such as childhood maltreatment, previous life events, dis-
ease episodes, and different psychopharmacological treatment schedules that often remain
unidentified and potentially reduce the power to detect true response biomarkers. Third,
genetic background, age, and sex are all factors that significantly impact transcription profiles
and other laboratory measurements, as well as treatment outcome [11].
In addition to the aforementioned problems, major psychiatric disorders, including MDD,
are primarily viewed as brain disorders, so the question of whether peripheral measures can be
informative for treatment response to centrally acting compounds such as antidepressants
continues to be matter of debate [12]. During recent years, evidence has emerged that disease-
and treatment-related changes may be reflected outside the central nervous system [13, 14],
revealing a potential role for appropriate animal models to support biomarker discovery in
MDD. To the best of our knowledge, neither an appropriate animal experimental approach
nor a translational approach systematically addressing the potential of biosignatures predicting
or tracking antidepressant treatment response has been published.
To overcome some of the limitations of past approaches, we here present a conceptually
novel approach that allows the selection of extreme phenotypes in an antidepressant-respon-
sive mouse strain (DBA/2J [15]) and uses these extreme groups to identify peripheral blood
biomarkers associated with behavioral treatment response, which are then tested in a human
patient cohort. This strategy exploits the advantages of a murine approach for the purpose of
biomarker discovery, i.e., (1) to investigate a highly homogeneous group of animals in which
differences in genetic background, age, and sex can be excluded, (2) to perform biomarker dis-
covery under conditions in which interindividual confounding environmental influences,
including drug plasma and brain levels, are reduced to a minimum and controlled for, and (3)
to allow correlations of peripheral biomarkers with behavior but also with peripheral and cen-
tral drug concentrations, and to test the overlap of blood and brain expression profiles. We
hypothesize that these standardized conditions will facilitate the identification of valid periph-
eral biomarkers for antidepressant treatment response and allow translation to humans.
Materials and methods
Ethics statement
Animal experimental approaches. All animal experiments were approved by the com-
mittee for the Care and Use of Laboratory Animals of the Government of Upper Bavaria, Ger-
many (AZ 55.2.-1-54-2532-127-11). All experiments were carried out in accordance with the
European Communities Council Directive 86/609/EEC.
Human studies. PREDiCT: The study was designed and conducted in accord with the lat-
est version of the Declaration of Helsinki. The Emory Institutional Review Board and the
Grady Hospital Research Oversight Committee gave ethical approval for the study design, pro-
cedures, and recruitment strategies (Emory IRB numbers 00024975 and 00004719).
Citalopram versus CBT: Written informed consent was obtained from all participants, with
the protocol conducted as approved by the Emory Institutional Review Board and registered at
clinicaltrials.gov (NCT00367341).
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Abbreviations: CRH, corticotropin releasing
hormone; dex, dexamethasone; FDR, false
discovery rate; FST, forced swim test; GR,
glucocorticoid receptor; HDRS, Hamilton
Depression Rating Scale; HPA, hypothalamus-
pituitary-adrenocortical; KEGG, Kyoto Encyclopedia
of Genes and Genomes; MDD, major depressive
disorder; PFC, prefrontal cortex; SSRI, selective
serotonin reuptake inhibitor.
Development of an animal experimental approach modeling the
heterogeneity in response to antidepressant treatment
Conceptual background. We hypothesized that within a large group of antidepressant-
treated mice (antidepressant-responsive strain DBA/2J), we would be able to stratify animals
into subgroups that are either responding exceptionally well (“responder”) to the antidepres-
sant treatment or that do not show a response at all (“nonresponder,” concept visualized in
Fig 1). The readout parameter for scoring antidepressant response was the forced swim test
(FST, also known as Porsolt test [16]). Importantly, searching for potential predictors of early
antidepressant response, a 14-day treatment was chosen according to the “early response phe-
notype” in clinical studies.
Animals and housing conditions
Experiments were carried out with male DBA/2J mice (n = 140) from Charles River, France.
On the day of arrival, the animals were 6–8 weeks old and from that day on were singly housed
in standard cages under a 12L:12D cycle (lights on at 0800 h) and constant temperature
(23 ± 2˚C) conditions. Food and water were provided ad libitum. Pharmacological treatment
of all animals started at an age of 9–11 weeks. Behavioral testing was performed at an age of
11–13 weeks. The experiments were carried out in the animal facility of the Max Planck Insti-
tute of Psychiatry in Munich, Germany, and approved by the committee for the Care and Use
of Laboratory Animals of the Government of Upper Bavaria, Germany. All experiments were
carried out in accordance with the European Communities Council Directive 86/609/EEC.
Experimental design
The sequential steps and experimental procedures are summarized in Fig 2, indicating the
number of animals for each experimental group. A large number of animals were treated twice
a day with either paroxetine (n = 90), a commonly used selective serotonin reuptake inhibitor
(SSRI) antidepressant or a vehicle (n = 50). On treatment day 15, the animals received their
Fig 1. Murine approach modeling heterogeneity of treatment outcome in the FST. This figure illustrates
the underlying hypothesis: in a large number of animals that are treated with an antidepressant, animals are
stratified into subgroups of extremes according to their time-floating behavior. To allow for the distinction of
effects truly related to the phenomenon of response (and not treatment per se), a second group of animals is
treated with a vehicle under identical conditions. FST, forced swim test.
https://doi.org/10.1371/journal.pbio.2002690.g001
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last drug administration at 6 AM and were subjected to a FST 4 hours later. Directly after the
FST, the animals were anesthetized with isoflurane and decapitated.
Oral stress-free antidepressant treatment and behavioral readout. The DBA/2J mouse
strain has previously been shown to respond to oral treatment with the commonly used SSRI
paroxetine under basal stress-free conditions [17], and this was the most important argument
in favor of paroxetine (5 mg/kg twice daily).
Animals were randomly distributed to the vehicle or paroxetine-treated experimental
group. Paroxetine (paroxetine hydrochloride; Sigma-Aldrich, Germany) or vehicle was volun-
tarily self-administered twice daily via customized palatable pellets (40 mg PQPellets, Pheno-
quest AG, Martinsried, Germany), with a concentration of 5 mg/kg body weight. To evaluate
the minimum effective dosage in our mouse strain, we included an additional group of animals
treated with 1 mg/kg paroxetine (paroxetine n = 29, vehicle n = 11) twice daily for comparison.
Consumption was monitored on a daily basis. Animals that did not voluntarily consume the
mouse pellets were excluded from the analysis.
The FST was performed on day 15 of the antidepressant treatment, 4 hours after the last
drug administration, between 10 AM and noon. Each mouse was placed into a 2-L glass beaker
(diameter, 13 cm; height, 24 cm) filled with tap water (22 ± 1˚C) to a height of 15 cm, so that
the mouse was not able to touch the bottom with its hind paws or tail. The duration of the test
was 5 min. The parameters floating, swimming, and struggling were scored by an experienced
observer who was uninformed regarding the treatment of the animals. Animals with the high-
est 20% of time floating were categorized as poor treatment responders, whereas animals with
the lowest 20% of time floating were categorized as good treatment responders (Fig 1).
Fig 2. Flowchart for the entire experimental procedure. Summary figure illustrating the sequential steps of experiments and analyses
applied in this study, indicating the experimental groups and group sizes for each condition. CORT, corticosterone; QC, quality control.
https://doi.org/10.1371/journal.pbio.2002690.g002
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Blood and brain tissue sampling procedure
Animals were anesthetized with isoflurane and killed immediately following the FST. Trunk
blood was collected individually in 1.5-mL tubes. Brains were rapidly dissected and frozen at
−80˚C.
Due to the complex character of the study, limitations in available specimens, stringent
quality control (QC), and exclusion of outlier data, we could not always achieve fully identical
sample and group compositions throughout all data analysis levels. This also explains the spo-
radic appearance of nonconcordant group sizes, which we consider a minor but unavoidable
drawback.
Paroxetine brain and plasma concentrations
Brain and plasma paroxetine concentrations were measured after extraction by high liquid
chromatography and quantifications. Paroxetine plasma concentrations were considered as a
covariate in the analysis of the microarray data. For details of the respective protocols, see [18].
High-performance liquid chromatography. High-performance liquid chromatography
(HPLC) analysis was performed using a Beckman 166 variable-wavelength ultraviolet (UV)
detector (Beckman Coulter, Inc., Indianapolis, IN), a Merck L-7480 fluorescence detector
(Merck KGaA, Darmstadt, Germany), and a Beckman gradient pump 126 Solvent Module
(Beckman Coulter, Inc., Indianapolis, IN) equipped with a Beckman autoinjector 508 auto-
sampler (Beckman Coulter, Inc., Indianapolis, IN) [18]. A Luna 5 μ C18(2) 250 × 4.6 mm col-
umn (Phenomenex, Torrance, CA) was used for separation; column temperature was set at
60˚C and the flow of the mobile phase was 1.0 mL/min. For chromatographic analysis of par-
oxetine and its metabolites, a mobile phase gradient was used and combined with determina-
tion of the substances and their metabolites by UV absorption or fluorescence. The coefficient
of variance was less than 15% for the different methods.
Quantification. Calibration of plasma samples was performed using spiked samples at
different concentrations [18]. Quantification was done by calculating the analyte: internal-
standard peak-area ratio. In addition, a regression model was fitted to the peak-area ratio of
each substance to internal standard versus concentration.
Corticosterone plasma concentrations
For determination of brain tissue concentrations of paroxetine, tissue from the cerebellum was
dissected and rapidly frozen on dry ice. The remaining trunk blood of each animal was col-
lected in labeled 1.5-mL EDTA-coated microcentrifuge tubes (Kabe Labortechnik, Nu¨m-
brecht, Germany). All blood samples were kept on ice until centrifugation at 8,000 rpm at 4˚C
for 15 min. After centrifugation, the blood plasma was transferred to new, labeled 1.5-mL
microcentrifuge tubes. All plasma samples were stored frozen at −20˚C until the determination
of corticosterone by radioimmunoassay (MP Biomedicals, Santa Ana, CA; sensitivity, 6.25 ng/
mL).
Statistics for data obtained in in vivo experiments
The data presented are shown as means + standard error of the mean, analyzed by the com-
mercially available software SPSS 16.0. For comparing 2 independent groups, data were ana-
lyzed with 2-tailed, independent samples Student t test in case of normal distribution of the
data; otherwise, nonparametric comparisons were applied (Mann–Whitney U test). For vari-
ables with more than 2 groups, 1-way ANOVA was performed followed by Bonferroni post
hoc testing. Correlations were analyzed with a 2-tailed, bivariate Pearson’s correlation analysis.
Biosignatures associated with antidepressant response
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As nominal level of significance, p< 0.05 was accepted. Values outside the 95% confidence
interval (CI) were defined as statistical outliers and excluded from the analyses.
For RNA extraction
Part of the blood was processed according to the PAXgene blood miRNA Kit manufacturer’s
instructions. Briefly, 350 μL of freshly collected trunk blood was immediately transferred into
1.5-mL tubes filled with 966 μL PAXgene solution (RNA stabilizer reagent), gently inverted 10
times, incubated at room temperature (RT) for 2–24 hours, and then stored at −20˚C before
ribonucleic acid (RNA) isolation. Volume ratio of RNA stabilizer reagent to blood samples
was kept at 2.76, according to the manufacturer’s protocol.
Whole blood RNA globin reduction. Blood consists of a heterogeneous cell population
of erythrocytes, granulocytes, and other peripheral mononuclear cells (PBMC). This heteroge-
neity makes it difficult to detect differences in gene expression levels. Furthermore, it is worth
mentioning that blood consists of a high amount of globin mRNA transcripts. This high
amount of globin mRNA transcripts can mask differences in other mRNA transcripts. After
the RNA isolation from whole blood, we applied the Ambion GLOBINclear-Mouse/Rat Kit.
Globin reduction was performed according to the manufacturer’s protocol. Input RNA was
quantified before the globin reduction with a Nanodrop spectrophotometer. Shortly, custom
biotinylated complementary oligonucleotides were mixed with globin RNA sequences from
RNA isolated out of whole blood and then annealed the oligonucleotides to α- and β-globin
transcripts. Streptavidin-coated paramagnetic beads were added to bind the biotinylated
duplexes and therefore removed the captured globin transcripts from the preparations of total
RNA. This globin-reduced RNA was then further processed and amplified and then used for
the microarray experiments.
Gene expression profiling in mice
Microarray analysis. After stratification of mice into good versus poor responder sub-
groups according to the abovementioned phenotypic criteria, gene expression profiling by
means of whole-genome gene expression microarrays (MouseWG-6 v2.0 Expression Bead-
Chip Kit, Illumina) was performed on globin-depleted RNA extracted from 3 groups of ani-
mals: good treatment responders (n = 12), poor treatment responders (n = 12), and vehicle-
treated animals (n = 12) (see Fig 2 for an overview of the groups). For comparison of transcrip-
tome profiles of peripheral blood and brain, prefrontal cortex (PFC) was punched from cryo-
sections of the same animals using a binocular microscope.
Gene expression profiling in mice
RNA quantification and QC. Globin-depleted total RNA was quantified with a Nano-
photometer (Nanodrop 2000, Fisher Scientific, Waltham, MA) and both quantified and quality
controlled by capillary gel electrophoresis (2100 Bioanalyzer, Agilent Technologies, Santa
Clara, CA; RNA 6000 nano Assay, Agilent Technologies, Santa Clara, CA). The obtained RNA
integrity numbers (RIN) were greater than 7.5 in all total RNA samples derived from blood
before globin depletion and dropped slightly after globin depletion (RIN> 6.3 for all samples
that were further analyzed).
RNA amplification and labeling. Globin-depleted RNA was labeled and linearly ampli-
fied to cRNA in a commercial form of the classical procedure by Eberwine. As input for the
Illumina TotalPrep-96 RNA Amplification Kit (Life technologies, Carlsbad, CA), 250 ng of
RNA was used, and sample processing followed the manufacturer’s protocol exactly. cRNA
was again quantified and quality checked as performed with total RNA. All samples underwent
Biosignatures associated with antidepressant response
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photometric analysis (Epoch Spectrophotometer with Take3 Trio Micro-Volume Plate, Bio-
Tek Instruments GmbH, Bad Friedrichshall, Germany) and a selected cross section of the sam-
ples was additionally checked on the Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Microarray hybridization. Following the manufacturer’s instructions (WGGEX Direct
Hybridization Assay Guide 11322355A), 1,500 ng of labeled cRNA was hybridized onto
whole-genome gene expression microarrays (MouseWG-6 v2.0 Expression BeadChip Kit, Illu-
mina, San Diego, CA). Sample randomization and alternating processing between the experi-
mental groups were applied in order to avoid technical bias being correlated with group
comparisons.
Microarray scanning and QC. Microarrays were scanned and intensity extractions were
computed using a BeadArray Reader (Illumina, San Diego, CA) via the BeadScan Software
with activated internal outlier detection and a scan factor of 1 (PMT = 478; PMTFactor = 1).
The extracted bead summary data provide gene expression levels from 45,281 array features
per sample. QC of microarray data was based on visual inspection of scan images, data distri-
butions, internal Illumina controls, pairwise scatter plots, and statistical outlier detection of
samples. Thereby, 3 samples (1 from the good responder group and 2 from the control group)
were excluded from further analysis.
Microarray data processing and analysis. For the samples fulfilling QC criteria, bead
summary scan data were filtered for detected probes with p-detection < 0.05 in at least 4 sam-
ples in the whole data set. Variables remaining numbered 20,412 and were variance stabilizing
normalization (vsn) transformed and normalized using the bioconductor R package “beadar-
ray.” Normalized and filtered data were imported into Qlucore Omics Explorer 2.3 (Qlucore,
Lund, Sweden) for exploration of batch effects and for inference testing. Principal component
analysis was used to identify batch effects and artifacts according to correlations of the sample
structure with putative confounders. Consequently, a mild technical bias was removed by
using bead chip ID as a covariate in ANOVA from blood samples analyses. Paroxetine concen-
trations were used as a second covariate to remove unwanted variance introduced by differ-
ences in the bioavailability of paroxetine. For some animals, blood paroxetine concentrations
were not available due to limitations in total blood amount. To impute those missing values, 4
blood concentrations used in the differential gene expression analysis were predicted from
regressing paroxetine concentrations from brain against blood. In the brain microarray data,
covariates were paroxetine concentration in brain, and “amplification batch.” For correlation
analyses of paroxetine concentrations with microarray data, paroxetine concentration as
covariate was omitted.
For inference testing, variables (individual microarray probes) were further filtered for vari-
ance of>5%, which left 4,966 variables for the good versus poor responder comparison and
6,664 for the paroxetine versus vehicle comparison. Statistical tests of microarray data were
based on 2 group comparisons using ANOVA with Benjamini-Hochberg based false discovery
rate (FDR)-analogue q-values (q< 0.1 and q< 0.05).
Annotation of microarray probes was done using the manufacturer’s annotation file (Mou-
seWG-6_V2_0_R2_11278593_A.bgx).
Visualization of microarray results. Microarray results were visualized as a volcano plot;
all 4,966 microarray probes that have been filtered for detection over background and variance
in the paroxetine blood data have been plotted. The x-axis displays the difference in residual
gene expression for normalized microarray data (variance stabilizing normalization, vsn). The
y-axis indicates the negative value of log 10 transformed q-values.
Gene regulation pattern analysis between tissues was performed using the R “stats” package
(functions: heatmap, dendrogramm, hclust, and dist). All significant probes from blood were
mapped to the brain array results. After removing probes with missing data in one of either
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tissue, 214 microarray probes remained for the analysis. Clustering was only performed for
microarray probes that are represented as rows in the plot. The agglomerative clustering is
based on the method “complete” and the use of a distance matrix with euclidean distances as a
dissimilarity parameter.
Impact of blood cell proportions in mice gene expression profiles
We assessed whether the observed gene expression profiles of good treatment responders and
poor treatment responders were related to changes in blood cell proportions in the mice using
CIBERSORT [19]. The input reference matrix of expression signature profiles of mouse tissue
was obtained using ImmuCC [20]. These statistical tools infer proportions of 25 types of
immune blood cell types.
Gene expression transcripts of antidepressant treatment response
tested in a human sample
To assess the relevance of the gene expression transcripts for antidepressant response differ-
ences in humans, we tested their predictive ability to classify response status in a human sam-
ple. The sample (n = 86) consisted of a subset of MDD patients treated with antidepressant
drug treatment over 12 weeks from 2 samples recruited at Emory University School of Medi-
cine (N = 74 from [21] and N = 12 from [22]). In both studies, patients followed a similar pro-
tocol and were randomized to either antidepressant drug treatment or cognitive behavior
therapy (CBT), with the difference that patients were randomized to CBT, duloxetine, or esci-
talopram in PReDiCT [21] and to CBT or escitalopram in [22]. Only the subset of patients in
the antidepressant treatment group with sufficient RNA quality at both time points was
included in this study. Please see S2 Table for a brief synopsis of demographic and clinical
parameters on the patients from clinical studies. Depression severity was assessed at baseline
and week 12 using the Hamilton Depression Rating Scale (17 items, HDRS-17). In both sam-
ples, blood was drawn at baseline and after 12 weeks of treatment into Tempus RNA tubes
(Applied Biosystems).
RNA was isolated from peripheral blood in a 96-well format using the magnetic bead-based
technology MagMAX for Stabilized Blood Tubes RNA Isolation Kit, compatible with Tempu
Blood RNA Tubes (Ambion/Life Technologies, Carlsbad, CA; cat# 4451893). RNA was quanti-
fied using the Nanophotometer, and quality checks were performed on the Agilent Bioanalyzer
(Agilent Technologies, Santa Clara, CA). Only samples with RIN 6 with clear 18S and 28S
peaks on the Bioanalyzer were used for amplification; the average RIN was 6.3 (SD of 0.668).
RNA was further processed for generation of biotin-labeled amplified RNA using the Amplifi-
cation Kit (Ambion/Life Technologies, Carlsbad, CA; cat# 4393543). cRNA was hybridized to
Illumina Sentrix Arrays HT-12 v4.0 arrays using the Illumina TotalPrep-96 RNA (Life technol-
ogies, Carlsbad, CA) and incubated overnight for 16 hours at 55˚C. Arrays were washed,
stained with Cy3 labeled streptavidin, dried, and scanned on the Illumina BeadScan confocal
laser scanner (Illumina, San Diego, CA). QC was performed using the bead-array package in R
for 86 samples and 47,282 probes. Probes with p-detection values of<0.01 in at least 10% of
the samples in the whole data set were removed. Remaining probes were normalized and
transformed using the vsn package in R. Not all samples were hybridized on the same batch,
and thus we corrected for chip number using COMBAT. A total of 17,725 transcripts and 86
samples remained after QC.
For the full drug-treated sample, 63 patients were classified as responders and 23 as nonre-
sponders, according to percent changes in HDRS-17 scores from baseline to week 12 (50%
or<50% change, respectively).
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Mouse gene expression transcripts (n = 259) resulting from the microarray analysis and
described in S1 Table were mapped to their human orthologue genes present in the Illumina
HT-12 arrays (n = 241). Because some genes are represented by more than one probe, 288
probes were included in final analyses. Prediction models were built as soft margin support
vector machines for classification using the e1071 packages in R with the parametrization
gamma = 0.001; cost = 10. Further analyses included only mouse transcripts at FDR of 5%
(n = 85). These were also mapped to their human orthologue genes (n = 77); 66 genes passed
QC in the human study, which were represented by 92 probes. The sample was equally divided
into training and test data sets for each of the analyses (probes at q< 0.1 and q< 0.05). Gene
expression repeated measures from the patients at baseline and week 12 were available; we
computed the absolute difference between the expression levels of the transcripts between
those time points and tested whether these differences were able to predict response to antide-
pressant treatment in the test data set. We permuted the response-status labels 10,000 times in
the training data set and predicted the response status in our test data. In addition, we com-
pared the obtained prediction accuracy of our selected classification features against 1,000 clas-
sification models derived from randomly sampled features. Random feature sets also consisted
of absolute difference in expression between baseline and week 12 of treatment and were size
matched to the selected feature set. Those data were the input for soft margin support vector
machine training and testing as indicated above.
Impact of blood cell proportions in human gene expression profiles
We assessed whether the observed gene expression changes in responders versus nonrespond-
ers were related to changes in cell proportions in the human samples using the Cell-type
Computational Differential Estimation CellCODE R package [23]. Separate components for
neutrophils, T cells, stimulated T cells, NK cells, dendrite cells, stimulated dendrite cells,
monocytes, B cells, and plasma cells were extracted using markers from the IRIS reference data
set provided by CellCODE.
Pathway analysis
Two available tools have been used for pathway analyses: DAVID (https://david.ncifcrf.gov/)
and Pathway-Express [24].
Both tools were used with a list of gene symbols previously shown to be significantly regu-
lated (q-value< 0.1) with differential paroxetine response and interrogated with respect to a
custom background that contained all microarray probes that have been used for computing
inferential statistics. The background contained probes that passed our detection and variance
filters.
Functional overlap of differential paroxetine response with dex-regulated
genes
To determine the function overlap of differential paroxetine response with dex-regulated
genes, we used data from a microarray experiment in male C57BL/6N mice at an age of 12
weeks (mean body weight 26.8 ± 0.1 g), in which animals were treated with 0.1 mg/kg dexa-
methasone i.p. or vehicle (N = 10 and 10) between 0900 and 1100 and sacrificed 4 hours later
[25]. Trunk blood was collected into microcentrifuge tubes containing PAXGene RNA stabi-
lizer solution and frozen at −20˚C. RNA was then extracted using the PAXgene blood miRNA
kit (PreAnalytiX), amplified using the Illumina Total Prep 96-Amplification kit (Life Technol-
ogy), and then hybridized on Illumina MouseRef-8 v2.0 BeadChips.
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Analyses were performed using custom scripts in R. First, a common content for both
microarray data sets was generated based on Illumina “Probe Ids.” Within that common con-
tent, differentially expressed microarray probes were identified for both contrasts using an
FDR threshold of q< 0.1. For the differential paroxetine response, 179 probes passed that
threshold. Then, the number of array probes overlapping with dex regulation by chance was
determined using 100,000 random sampled gene sets of size N = 179. For each trial, the overlap
to the fixed dex-regulated gene list (N = 1,882) was determined and all the results were finally
compared to the overlap of paroxetine response genes with dex-regulated genes; this was done
by counting the number of sampled sets that showed higher overlap (>134) than the differen-
tial gene list.
In addition, a 2 × 2 contingency table was computed for dex regulation and paroxetine
response and these numbers were further used to perform a hypergeometric test.
Calculation of statistical significance for a possible directionality of gene regulation was per-
formed using a binomial test.
Results
Modeling heterogeneity in antidepressant treatment response in mice
In order to detect the minimum effective dosage of paroxetine for the DBA/2J strain, 2 paroxe-
tine concentrations (1 mg/kg body weight or 5 mg/kg body weight, twice daily) were tested in
a pilot study. The lower paroxetine concentration (n = 29) failed to produce a significant
behavioral treatment effect in the FST. The only parameter that was altered with the 1 mg/kg
dosage was body weight (T39 = −2.490, p< 0.05). Behavioral data, neuroendocrine measure-
ments, and body weight are shown in S1 Fig.
A dosage of 5 mg/kg evoked a significant antidepressant-like response in the FST (Fig 3).
The following data were all collected from animals treated with 5 mg/kg paroxetine, which we
considered to be the minimum effective dosage for the DBA/2J strain.
Behavioral heterogeneity of paroxetine-treated mice allows stratification into good ver-
sus poor treatment responders. Paroxetine-treated animals showed a significant reduction
in the time floating (Fig 3A) (T80.701 = 9.157, p< 0.000) and a significant increase in the time
struggling (Fig 3B) (T102.624 = −4.496, p< 0.000). Furthermore, there was a large heterogeneity
within the paroxetine-treated animals (Fig 3C), thus allowing selection of extreme subgroups
(animals with low time floating were considered “good responders;” animals with a high time
floating were considered “poor responders” [20% extremes]).
Physiological and neuroendocrine parameters. Paroxetine-treated animals gained sig-
nificantly more body weight compared to the vehicle group (T105 = −8.356, p< 0.000) (S2
Fig). However, there was no significant difference in body weight gain between the responder
and nonresponder groups (S2 Fig).
Plasma corticosterone concentrations were assessed directly after the 5-minute FST. No sig-
nificant difference in corticosterone plasma concentrations was detected between vehicle- and
paroxetine-treated animals (S2 Fig) or between the subgroups of good- versus poor-respond-
ing animals (S2 Fig).
Paroxetine plasma and brain concentrations
There was no significant difference in plasma paroxetine concentrations between the good
and poor treatment responder (p = 0.19). For paroxetine brain concentrations, a significant
difference between good and poor responders could be detected (p< 0.05) (S3 Fig). Paroxetine
brain and plasma concentrations were closely correlated (r = 0.94; p< 0.0001) (S3 Fig).
Despite the lack of statistical association, we included plasma paroxetine concentrations as a
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covariate in further analyses on the transcriptome profiles in peripheral blood samples. Brain
paroxetine concentrations were used as covariates in analyses of PFC samples.
Microarray analysis in peripheral blood
To identify signature gene expression profiles characteristic of the animals’ responder status,
gene expression data sets of vehicle-treated animals, good responders, and poor responders
were created by whole-genome gene expression microarray analysis on blood samples and
analyzed (n[vehicle] = 12, n[good] = 12, n[poor] = 12). We evaluated both treatment effect
and response status with respect to antidepressant treatment and with respect to paroxetine
plasma concentrations. We also investigated whether paroxetine brain or plasma concentra-
tions might have an effect on gene expression levels. Linear and quadratic regression analyses
did not reveal any microarray probe that showed significant correlations with the related
plasma paroxetine levels when controlling for multiple testing. No significant influence of par-
oxetine concentrations on gene expression profiles was observed. Nevertheless, identified tech-
nical batch effects in the data and measured paroxetine drug concentrations in blood were
used as covariates in an ANOVA-based statistical model.
Although no robust gene regulation was apparent when the treatment group (independent
of response) was compared to the control group, there was a pronounced effect within the
treatment group. We were able to detect a set of 259 transcripts that showed a significant
Fig 3. A 14-day paroxetine treatment significantly reduces depression-like behavior in the FST. (A)
Paroxetine-treated animals showed a reduction in time floating compared to vehicle-treated animals. (B)
Paroxetine significantly increased active coping strategies, i.e., time struggling, compared to vehicle-treated
animals. (C) Identification of different responder groups according to their performance in the FST. Animals
indicated in the red squares are referred as good and poor treatment responders. Animals that showed a very
high time floating represent the poor treatment responder, whereas animals that showed a very low time
floating represent the good treatment responder. Animals indicated in the dotted-line square represent
internal control groups. Animals within the vehicle-treated group served as a vehicle-treated control group.
* indicates significant difference between the vehicle-treated control group and the paroxetine-treated group,
p < 0.000. All raw data for Fig 3 are available in S2 Data. FST, forced swim test.
https://doi.org/10.1371/journal.pbio.2002690.g003
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difference in expression due to antidepressant response status at a false discovery controlled
significance level of 10% (q< 0.1) (Fig 4; S1 Table), of which 85 had q< 0.05 (S1 Table).
We then aimed to see whether the observed gene regulation patterns in peripheral blood
might overlap with effects observed in the PFC from the same animals. To test this, we first
performed a cluster analysis on the difference in expression between the responder groups in
the set of differentially regulated genes in blood. We then compared the results for these tran-
scripts to the difference in expression between these 2 groups measured in PFC brain tissue in
the same animals. The results are summarized in a heat map in Fig 4 and indicate that, within
the selected gene set, there is no major common gene regulation pattern associated with
response status between both tissues.
Impact of blood cell proportions in mice gene expression profiles
No significant differences in immune cell subtypes between the different response groups were
detected using CIBERSORT [19] and ImmuCC [20] (see S3 Table).
Impact of blood cell proportions in human gene expression profiles
No significant change in immune cell subtypes using CellCODE [23] was associated with the
response groups in the human sample (see S4 Table). Therefore, none of the estimated cell
proportions were included in further analyses.
Murine signature gene expression transcripts predict antidepressant
treatment response in the human sample
In the next step, we determined whether this transcriptional profile identified in the mouse
model would also be relevant in the human data set. Therefore, we tested whether changes in
the mRNA expression of the human orthologues of transcripts at FDR of 10% and at FDR of
Fig 4. Differential gene expression in animals stratified for behavioral treatment response to chronic
paroxetine treatment. (A) Volcano plot showing results from blood samples. The biological effect size
(difference in expression) is plotted against statistical significance (as negative log 10 transformed values of
the FDR-based q-value). Regarded as significantly regulated, 259 probes with q-values < 0.1 are colored
according to their difference in expression. (B) Heat map comparing patterns of differential gene expression in
blood and prefrontal cortex. Each row in the plot represents the difference in expression of 1 microarray probe
between poor and good responders in both blood and prefrontal cortex. The array probes are ordered
according to agglomerative hierarchical clustering, but no large common gene regulation patterns are
revealed between the 2 tissues. Scale for color coding difference in expression is identical for (A) and (B). All
raw data for Fig 4 are available in S1 Data. FDR, false discovery rate.
https://doi.org/10.1371/journal.pbio.2002690.g004
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5%, separately, are associated with response to antidepressant treatment. Differences in expres-
sion profiles from baseline to week 12 when using human orthologues of transcripts at FDR of
10% allowed prediction of response status (at least 50% improvement in HDRS-17 from base-
line to week 12 for responders) with an accuracy of 76%, using all patients treated with antide-
pressant. The prediction persisted after we permuted the response-status labels 10,000 times
(pperm = 0.0328). When a more stringent FDR of 5% cutoff was applied to the mouse tran-
scripts, the corresponding human orthologues predicted response status with an accuracy of
81% in the human sample. The prediction persisted after we permuted the response-status
labels 10,000 times (pperm = 0.0018).
After showing that expression levels of the antidepressant response genes identified from
mice are also informative for classification in a human sample, we further analysed the quality
of the mouse-based feature selection in the human data set. For this, we compared the classifi-
cation accuracy of our identified antidepressant-response features to classification accuracy
given by randomly chosen and size-matched sets of gene expression probes in the human sam-
ple (Fig 5). In analogy to the previous classification approach, we used differences in gene
expression from baseline to week 12 in 1,000 random sets of gene probes. Only 25 random
gene probe sets showed higher or equal prediction accuracy than our feature panel selected
from the animal model. This suggests that the information derived from the mouse experi-
ments allowed the selection of transcripts for which the classification accuracy is better than
for random gene expression background (pperm = 0.026).
Functional annotation
For functional annotations of the microarray results, we performed pathway analyses and
included an overrepresentation analysis with DAVID, and we conducted a second analysis
using Pathway-Express. The latter accounts for pathway topology and biological effect
size. In both approaches, no significant results passing our threshold criteria were found.
The top overrepresented categories in DAVID were entities associated with general gene
transcription and did not reach significance levels. Although Pathway-Express showed for-
mally significant results for a few specific Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways, we excluded them because less than 2% of the pathway genes were
regulated.
Genes regulated by dexamethasone are enriched in paroxetine
treatment responsive genes
We next integrated our results with another microarray data set that we had previously gener-
ated. Those data originated from mouse blood samples taken from animals that had been
treated with the glucocorticoid receptor (GR) agonist dexamethasone (dex [25]). To test
whether GR activation responsive genes are overrepresented in our antidepressant response
gene set, we used a permutation approach and computed the overlap of dex-regulated genes
with the paroxetine response genes and compared it to matched random gene sets sampled
from the paroxetine array results (Fig 6). Based on 2,852 array probes that constituted a
common content for both independent data sets, 179 array probes of the 259 response associ-
ated probes could be used for this analysis. The overlap between the probes significantly regu-
lated between the responder group and the ones regulated following dex administration was
134 out of 179. Within 100,000 trials of drawing random gene sets of 179 probes, there were
only 70 instances in which a higher overlap occurred. This reflects a permutation-based FDR
of 7e-4 for enrichment of dex-regulated array probes in paroxetine response probes. A
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hypergeometric test yielded a p-value of 5.6e-4, further supporting an enrichment of GR-
responsive transcripts among response-associated genes.
Standard enrichment analysis does not take into account the direction of gene regulation,
and we were interested to see whether paroxetine response and dex regulation showed a direc-
tional overlap. Of the 134 array probes that are significantly regulated by dex and are, at the
same time, between the paroxetine response groups, only 38 had a mismatch in the direction
of the putative regulation. The majority of the regulated genes (N = 96) are regulated in the
same direction in both conditions, and based on a binomial distribution, such a result could
not be observed if both outcomes (same and opposite regulation) had the same probability
(p = 7.2e-07). Thus, we can conclude that there is a common direction of gene regulation for
dex treatment and paroxetine response.
Fig 5. Classification features selected from differential gene expression in a mouse model for
antidepressant treatment response are informative for treatment response in a human gene
expression data set. Histogram shows the distribution of prediction accuracy over 1,000 simulated
classification models that were computed with randomly chosen gene expression probe sets from human
gene expression data (median prediction accuracy = 69.77%). The red dashed line marks the observed
prediction accuracy (76.74%) when using our informed feature selection to build classifiers. Because only 25
of the randomly chosen feature sets yield equal or better classification results, the predictive ability of our
features selected from the presented mouse model is significantly greater than expected by chance
(p = 0.026). All raw data for Fig 5 are available in S1 Data.
https://doi.org/10.1371/journal.pbio.2002690.g005
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Discussion
The goal of the present study was to gain insight into the biology of variations in response to
antidepressant treatment and to describe molecular signatures associated with response, ulti-
mately aiming at the identification of predictors of treatment outcome. Based on a conceptu-
ally novel translational approach, starting with stratification into extreme phenotypes in the
mouse, we were able to identify common—i.e., conserved across species—informative tran-
script sets associated with antidepressant treatment outcome. Intriguingly, we finally show
that GR-regulated genes are significantly enriched in this cluster of antidepressant-response
genes, pointing to the involvement of GR sensitivity as a potential key mechanism in shaping
transcriptional changes and clinical response to antidepressant treatment.
Modeling heterogeneity of antidepressant response in the mouse: The
approach
There are 2 obvious gaps of knowledge in depression treatment, namely (1) the lack of bio-
signatures predicting antidepressant response and (2) the lack of knowledge of the molecular
mechanisms mediating the response to antidepressant pharmacotherapy. The latter is of par-
ticular importance for the eagerly awaited discovery of conceptually novel antidepressant treat-
ment strategies, which can only be rationally realized with a deeper understanding of the
molecular mechanisms underlying clinical response [26].
In recent years, the unbiased, i.e., genome-wide, screening to identify genetic factors that
could assist in the prediction of an individual’s drug response has been a major focus in
Fig 6. Enrichment of dexamethasone-regulated genes. Histogram of 100,000 random samples indicates
that paroxetine response genes show higher overlap with dex-regulated genes than expected by chance. The
overlap between differential microarray probes from paroxetine-response and dex-regulated microarrays is
134 and this threshold is indicated as a vertical red dashed line. In this simulation, on average, 115 probes do
overlap by chance and in 70 samples, the random overlap is higher than the tested one. All raw data for Fig 6
are available in S1 Data. dex, dexamethasone.
https://doi.org/10.1371/journal.pbio.2002690.g006
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depression research. Despite tremendous efforts, however, the results are fairly modest in
identifying predictive genes in large genome-wide association studies [27–29] and even in a
meta-analysis [6]. Instead, Tansey et al. [30] recently presented data implicating a highly poly-
genic architecture involving many common variants scattered across the genome, none of
which have very large effects but cumulatively contribute to a substantial proportion of varia-
tion in antidepressant response. So far, only a few small studies provided first evidence that
biochemical information (e.g., metabolomics) could add to the panel of markers predicting
response to a particular antidepressant in patients [31], suggesting that alternative strategies
need to be explored.
However, studies to investigate the neurobiology of antidepressant treatment response have
been hampered by the fact that no appropriate animal model addressing this issue had yet
been described. Therefore, we embarked upon the development of an animal experimental
approach modeling the heterogeneity in response to antidepressant treatment as closely as pos-
sible. In contrast to studies in patients, this model approach both enables an in-depth analysis
of the neurobiological mechanisms shaping individual antidepressant response in the central
nervous system and searches for peripheral biosignatures associated with treatment response.
There are different approaches to model depression-like phenotypes (i.e., symptoms of depres-
sion) in the mouse. While induction of depression-like symptoms following exposure to differ-
ent types of stress, e.g., chronic social defeat or chronic mild stress is one possible approach,
the use of mouse strains with high innate anxiety- and depression-like behavior is also com-
monly accepted. The selection of the DBA/2J mouse strain, with its well-described high innate
anxiety and responsiveness to antidepressant treatment [17], enabled us to perform the phar-
macological treatment under basal conditions, i.e., without the need to subject the animals to
an additional stress procedure that might have influenced the transcriptome data. A combina-
tion of stress exposure and antidepressant treatment within our approach would not allow us
to identify the individual contribution of these 2 factors to the phenotype. Nonetheless, a com-
parison of stress-related and antidepressant response–related molecular events could enable
the identification of shared molecular pathways.
Oral treatment with the SSRI paroxetine significantly reduced—as expected—depression-
like behavior. Remarkably, in addition to the overall antidepressant-like effect on promoting
active coping strategies in the FTS, we detected a high variability in the behavioral outcome.
Although the neurobiological mechanisms underlying antidepressant-induced behavioral
changes in the FTS still are not fully understood [32], we here used the FST as the laboratory
animal equivalent of treatment response because it is the most commonly used test to screen
for antidepressant efficacy in rodents [16]. Comparable approaches for stratification and
extreme case sampling in animal models have been successfully introduced in the field of stress
research [33], and during recent years, they have enabled the identification of a number of key
mechanisms shaping individual susceptibility to stress [34, 35]. We considered plasma paroxe-
tine concentration as a covariate on our microarray analyses, but we were not able identify a
significant influence on the gene expression profile associated with treatment response.
The selection of a rodent approach for biomarker discovery in psychiatric disorders has the
advantage of minimizing potentially confounding variables, which, in clinical depression stud-
ies, so far have impeded biomarker discovery [12]. Due to the standardized experimental con-
ditions, factors such as sex, age, and additional environmental factors, including
pharmacological pretreatment, the time of day at which the blood sample is taken, physical
exercise, food, and many others [36], can be strictly controlled for, thus enabling the detection
of true response biomarkers in a hypothesis-free approach. In a second step, these murine bio-
markers can then be validated in the human population. Given the complexity of identifying
true biomarker candidates in psychiatric disorders, the need to strengthen potential candidates
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by cross-species approaches [37] and to validate those in independent cohorts is considered
crucial [38].
Translation to the patient: Murine signature gene expression transcripts
predict antidepressant treatment response in the human sample
Aiming to enable a translational approach, we focused on the identification of transcriptome
signatures in the periphery, because only those are relevant for clinical application. Several
studies have investigated the use of human peripheral blood cells as surrogate material for dif-
ferent organs and tissues, including the central nervous system [39–41]. However, inconsistent
results have been reported as to the overlap between transcriptome profiles in peripheral blood
and brain [14].
To address issues of cross-tissue relevance, we compared peripheral transcriptome signa-
tures with expression profiling data of the PFC of the same good- and poor-responding ani-
mals. We did not find any major common response status-associated gene regulation pattern
between both tissues. We thus hypothesize that in depression treatment, blood cells might act
as sentinels of treatment response but are not generally informative about central regulation
processes, at least not in the PFC.
In the next step and as a proof of concept, we sought to evaluate the relevance of the murine
transcriptional signature associated with antidepressant treatment response in a human data
set. Using a powerful within-participant approach investigating longitudinal transcription
changes between baseline and week 12 of antidepressant treatment, we tested whether mRNA
expression of the human orthologues of these transcripts changes with antidepressant treat-
ment in peripheral blood in a subset of 2 human studies [21, 22]. Differences in expression
profiles from baseline to week 12 of the human orthologues selected on the basis of the murine
transcript signature allowed prediction of response status (percent change in HDRS-17 from
baseline to week 12) with an accuracy of 76% in the human sample. Using a permutation strat-
egy, we also showed that our set of transcripts was more likely to predict treatment outcome
correctly than random sets of transcripts. We thus show the suitability of an appropriate ani-
mal experimental approach for the discovery of peripheral treatment response biomarkers.
While promising, our findings certainly require validation in independent samples of patients
with MDD. One aspect that needs more detailed investigation in future studies is the precise
time course and stability of response-associated transcript changes, as we here integrated
murine transcript data following 2 weeks of antidepressant treatment with patient data over a
12-week treatment course.
Modulation of GR sensitivity as underlying mechanism shaping
response to antidepressant treatment
The available evidence makes a compelling case implicating dysregulation of the stress hor-
mone system, the so-called hypothalamus-pituitary-adrenocortical (HPA) system, in the path-
ogenesis of MDD [42, 43]. Moreover, considerable evidence has accumulated suggesting that
normalization of the HPA system might be the final step necessary for stable remission of
the disease [44], and it was further hypothesized that antidepressants may act through normal-
ization of the HPA system function [45]. A recent study provided evidence that hormone-
independent activation of the GR is involved in the therapeutic action of fluoxetine [46], sup-
porting the neurobiological link between GR signalling and antidepressant action.
We could not detect any difference in corticosterone plasma concentrations between good
and poor responders to paroxetine treatment directly after the FTS challenge, although assess-
ment of plasma corticosterone concentrations at 1 time point, i.e., 5 min after the FST, does
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not exclude potential dynamic changes in HPA system response (i.e., changes in the rise of
corticosterone or HPA system feedback following initial activation). Evidence from measure-
ments of HPA system activity in depressed patients, however, supports the notion that in vivo
challenges such as the combined dexamethasone/corticotropin releasing hormone challenge
test (Dex-CRH test) are superior to single baseline measurements of peripheral glucocorticoid
concentrations in discriminating between depressed patients and healthy controls as well as
treatment responders versus nonresponders. In addition, recent investigations have shown
that dex-stimulated gene expression is a sensitive marker of GR-resistance in MDD [13] and
that common genetic variants that modulate the initial transcriptional response to GR activa-
tion increase the risk for depression [25]. Therefore, we tested for an enrichment of GR-
responsive genes in our antidepressant response gene set, a finding that could point to
increased GR sensitivity in good- versus poor-responding animals. We demonstrated that
(1) GR-regulated genes are significantly enriched in our cluster of antidepressant-response
genes and (2) there is a common direction of gene regulation for dex treatment and paroxetine
response. Our data are in line with a large body of previous evidence pointing to the normali-
zation of GR resistance as an important feature of the clinical response to antidepressant treat-
ment [43, 47] and support the intriguing hypothesis that antidepressants could stimulate
resilience-promoting molecular mechanisms [48].
Conclusion and perspectives
Biomarkers or biosignatures, respectively, would not only allow monitoring of antidepressant
treatment response in clinical practice but they also could assist in the evaluation of drug
actions at an early stage in clinical trials of novel agents that are frequently marred by late attri-
tion [49]. In particular, identifying biomarkers of response will be essential for assessing target
engagement of novel mechanisms. We submit that our approach opens up the opportunity to
generate a unique database for putative biosignatures predicting response to be assessed and
validated in larger patients’ samples.
In conclusion, we expect this translational approach to serve as a template for the discovery
of improved and tailored treatment modalities for depression in the future.
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S1 Fig. Neuroendocrine, physiological, and behavioral parameters following treatment
with low-dose paroxetine (1 mg/kg BW, twice daily). (A) Twenty-eight days of 1 mg/kg BW
paroxetine treatment led to an increase in body weight in the paroxetine-treated animals. (B)
Corticosterone levels were not altered due to the treatment. (C) Paroxetine treatment led to a
trend in reducing the time spent floating in the treated animals compared to the control
group. (D) Chronic treatment did not alter the time spent struggling in the paroxetine-treated
group.  significant correlation, p< 0.05. All raw data for S1 Fig are available in S2 Data. BW,
body weight.
(TIF)
S2 Fig. Impact of 14-d paroxetine treatment on physiological and neuroendocrine parame-
ters. (A) After 14 d of paroxetine treatment, animals treated with the SSRI gained significantly
more body weight compared to the vehicle-treated control group. (B) No significant difference
in body weight gain was found between the responder groups due to the paroxetine treatment.
(C) Corticosterone levels were assessed in blood plasma during the circadian nadir in the
morning directly after the FST. We did not find any significant difference in corticosterone
levels between vehicle- and paroxetine-treated animals. (D) While comparing the corticoste-
rone levels in the different responder groups, no difference was found between the groups.
Data are represented as mean + SEM.  significantly different from vehicle treated animals,
p< 0.000. All raw data for S2 Fig are available in S2 Data. FST, forced swim test; SEM, stan-
dard error of the mean; SSRI, selective serotonin reuptake inhibitor.
(TIF)
S3 Fig. Paroxetine brain and plasma concentrations following 14 d of antidepressant treat-
ment. (A, B) ANOVA analysis showed a significant association of responder status with both
plasma and paroxetine concentrations. In the post hoc analyses, only brain tissue concentra-
tions of paroxetine showed a significant difference between good responders and poor
responders. (C) Paroxetine brain and plasma concentrations were closely correlated (r = 0.94).
All raw data for S3 Fig are available in S2 Data.
(TIF)
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